

Cinacalcet + CYP1A2-remmers

M718

Bron	Pagina	Ref.nr.	Bewijs Effect (omschrijving + letter)		
Hansten	-				
Stockley ed. 6	-				
Extra					

Opmerkingen

SPC Mimpara: cinacalcet is substraat van CYP3A4 en CYP1A2; het remt CYP2D6 sterk. Het effect van CYP1A2-remmers (bv fluvoxamine, ciprofloxacine) op de plasmaspiegel is niet onderzocht. Dosisaanpassing kan nodig zijn bij sterke CYP1A2-remmers.

Roken induceert CYP1A2; bij rokers is de klaring ong. 38% hoger dan bij niet-rokers.

EPAR Mimpara: geen details. "The interaction potential for cinacalcet has only been investigated in part. The only *in vivo* study contributing to the assessment of interaction on cinacalcet is the ketoconazole study. The effect of a potent CYP1A2 inhibitor (e.g. fluvoxamine, ciprofloxacin) has not been evaluated and it is not known, and a clinically relevant effect on cinacalcet clearance cannot be excluded. The following is included in the SPC: "caution should be exercised when cinacalcet is administered concomitantly with strong inhibitors or inducers of CYP3A4 and/or CYP1A2. Dose adjustment of cinacalcet may be necessary".

IDIS/PubMed: levert niets op.

Risicogroep	
Incidentie	

	Interactie	Actie	Datum
Beslissing WFG	Nee	Nee	6 december 2005